• Y-27632 Dihydrochloride: ROCK Inhibitor for Advanced Cell Wo

  2026-07-25

  Y-27632 dihydrochloride accelerates stem cell viability, organoid formation, and invasion modeling by offering potent, selective ROCK inhibition with outstanding reproducibility. Discover protocol enhancements, troubleshooting, and innovations inspired by recent gut-brain axis research—all leveraging APExBIO’s trusted product portfolio.

• Nelfinavir Mesylate: HIV-1 Protease Inhibitor for Advanced R

  2026-07-24

  Nelfinavir Mesylate stands out as a dual-purpose, high-potency HIV-1 protease inhibitor with unmatched utility in both antiviral and cell death pathway research. Its robust quantitative benchmarks, ability to sensitize cells to ferroptosis, and reproducible performance make it indispensable for innovators seeking translational leverage.

• Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO): Pract

  2026-07-24

  The Protease Inhibitor Cocktail (EDTA-Free, 200X in DMSO) is designed to prevent protein degradation during extraction workflows while maintaining compatibility with divalent cation-dependent assays. It should be used when broad-spectrum protease inhibition is required, but not when metalloprotease inhibition via EDTA is necessary. Researchers benefit from its concentrated, EDTA-free formulation for applications such as Western blotting, co-immunoprecipitation, and phosphorylation analysis.

• RIG-I Drives Renal Fibrosis via c-Myc and Fibroblast Activat

  2026-07-23

  This study reveals that RIG-I, an intracellular RNA sensor, exacerbates renal interstitial fibrosis by promoting inflammatory cytokine production in tubular epithelial cells and activating c-Myc-mediated TGF-β/Smad signaling in fibroblasts. The findings highlight novel molecular links in chronic kidney disease progression and identify RIG-I as a potential target for antifibrotic intervention.

• A High-Throughput Surrogate Model for BBB Permeability Predi

  2026-07-23

  This study introduces a robust in vitro blood-brain barrier (BBB) model based on LLC-PK1-MOCK/MDR1 cells, enabling high-throughput prediction of brain penetration for CNS drugs. By integrating lysosomal trapping correction, the model closely mirrors in vivo drug distribution, streamlining early-stage CNS drug screening and reducing dependency on animal studies.

• Molidustat (BAY85-3934): Optimizing HIF Stabilization Workfl

  2026-07-22

  Molidustat (BAY85-3934) unlocks robust, physiologically relevant HIF stabilization for renal anemia and hypoxia research. This article delivers actionable protocol guidance, experimental troubleshooting, and cross-study insights to maximize translational impact using APExBIO’s validated compound.

• Fluorouracil (Adrucil) in Solid Tumor Evolution: Precision T

  2026-07-22

  Explore how Fluorouracil (5-Fluorouracil) enables advanced modeling of therapeutic heterogeneity in colon and breast cancer research. Uncover novel assay strategies grounded in recent genomic findings and learn how APExBIO's formulation advances reproducibility.

• GKT137831: Dual NADPH Oxidase Nox1/Nox4 Inhibitor in Redox P

  2026-07-21

  GKT137831 empowers researchers to precisely inhibit Nox1 and Nox4, dissecting reactive oxygen species dynamics in advanced models of vascular remodeling and fibrosis. Its nanomolar potency, workflow flexibility, and troubleshooting versatility make it a gold standard for translational redox research.

• Torin2: Precision mTOR Inhibitor for Advanced Cancer Researc

  2026-07-21

  Torin2 stands out as a next-generation mTOR inhibitor, offering unparalleled selectivity and potency for dissecting mTOR-driven pathways in cancer research models. Its robust performance in apoptosis assays and unique compatibility with mechanistic studies—such as those exploring active cell death signaling—enables reliable, reproducible insights that outpace legacy inhibitors.

• Berberine & Evodiamine Target TAS2R38/TRPV1 in GERD Inflamma

  2026-07-20

  This study reveals that berberine and evodiamine synergistically ameliorate gastroesophageal reflux disease (GERD) by modulating TAS2R38 and TRPV1 pathways, suppressing inflammation and restoring epithelial barrier integrity. The findings clarify the mechanistic role of bitter taste and TRPV1 receptor signaling in esophageal injury, supporting new molecular targets for GERD intervention.

• Rapamycin (Sirolimus): Protocols and Innovations for mTOR In

  2026-07-20

  Rapamycin (Sirolimus) enables high-precision modulation of mTOR signaling, driving advanced cell signaling and metabolic research. Explore optimized workflows, troubleshooting strategies, and the latest insights from autophagy and mineralization studies.

• ICAA Mitigates Cardiac Hypertrophy via RIP3/CaMKII Pathway I

  2026-07-19

  This study establishes isochlorogenic acid A (ICAA) as a direct inhibitor of RIP3, suppressing the RIP3/CaMKII pathway to alleviate angiotensin II-induced cardiac hypertrophy in vitro and in vivo. These findings introduce RIP3 as a novel therapeutic target and broaden mechanistic understanding for cardiovascular disease research.

• Lambda Protein Phosphatase: Precision Tools for Circadian Me

  2026-07-18

  Explore how Lambda Protein Phosphatase (RNase-free) empowers translational researchers to dissect the phosphorylation-dependent regulation of circadian clock proteins like BMAL1, integrating mechanistic insight with actionable guidance for protein modification validation, experimental design, and translational strategy.

• ML365: Selective TASK1 Inhibitor for Neurophysiology Researc

  2026-07-17

  ML365 (2-methoxy-N-(3-(3-methylbenzamido)phenyl)benzamide) is a potent, selective TASK1 potassium channel inhibitor used in ion channel pharmacology. It demonstrates nanomolar inhibitory activity and strong selectivity, making it valuable for neurophysiology and cardiopulmonary research. Recent evidence supports its utility in modulating neuroinflammation via NLRP3 inhibition.

• Nifedipine (BAY-a-1040): Bridging Calcium Inhibition to Tran

  2026-07-17

  Explore how Nifedipine (BAY-a-1040) enables translational breakthroughs by integrating mechanistic calcium influx inhibition with advanced modeling of metabolic adaptation. This thought-leadership article connects cutting-edge hepatic research, iron metabolism, and antifungal applications—offering actionable guidance for researchers seeking to drive clinical innovation.

449 records 10/30 page Previous Next First page 上5页 678910 下5页 Last page